SANDOZ, a global leader in generic and biosimilar medicines, has welcomed a positive PBAC recommendation for Jubbonti (denosumab) and Wyost (denosumab) to be included in the Pharmaceutical Benefits Scheme (PBS), effective 01 Aug this year.
Jubbontiis approved for treatment of osteoporosis and Wyost for treatment of cancer-related bone diseases.
"We are thrilled to receive a positive recommendation from the PBAC," said Clint Holland, GM Sandoz ANZ.
"This reflects our dedication to improving patient outcomes through accessible treatment options at Sandoz.
"Jubbonti and Wyost will play a crucial role in the management of osteoporosis and cancer-related bone disease," he said.
Over 850,000 Australians are affected by osteoporosis, resulting in more than 193,000 bone fractures annually.
Meanwhile, for the 30% of people with breast cancer and 18% with prostate cancer who develop bone metastases during their illness, denosumab can help prevent serious bone complications.
The reference medicine for Jubbonti is Prolia, and for Wyost is Xgeva, with the biosimilars approved for the same indications.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 25
